

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



Abbisko Cayman Limited
和譽開曼有限責任公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
TWO MAJOR CLINICAL UPDATES OF PIMICOTINIB (ABSK021)
WILL BE PRESENTED AT THE 2023 CTOS ANNUAL MEETING

Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. (“**Abbisko Therapeutics**”), a subsidiary of the Company, announced that it will present two major clinical updates of pimicotinib (ABSK021) at the 2023 Connective Tissue Oncology Society (“**CTOS**”) Annual Meeting.

This is a voluntary announcement made by the Company. The Group cannot guarantee that pimicotinib (ABSK021) will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, October 30, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive directors; Ms. Tang Yanmin as a non-executive director; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.

ABBISKO WILL PRESENT TWO MAJOR CLINICAL UPDATES OF PIMICOTINIB AT THE 2023 CTOS ANNUAL MEETING

On 30 October 2023, Abbisko Therapeutics announced that two major clinical updates of its self-developed next generation CSF-1R inhibitor pimicotinib (ABSK021) will be presented at the 2023 CTOS annual meeting, which will be held in Ireland from November 1 to 4, 2023. The two clinical updates include reporting the design of the pivotal global multi-center Phase III clinical trial and the further update of the Phase Ib clinical trial of pimicotinib. A plenty of achievements have been made since the release of pimicotinib clinical data at the 2022 CTOS.

Abbisko Therapeutics will present below information at this CTOS meeting:

Abstract ID: 1572315

Title: MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR

Category: Trials in Progress

Abstract ID: 1571943

Title: UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B

Category: Medical & Pediatric Oncology and Trials

About Pimicotinib

Pimicotinib is a novel, orally available, highly selective and potent small molecule CSF-1R inhibitor, independently self-developed by Abbisko Therapeutics. It has been granted the breakthrough therapy designation (BTD) and Priority Medicine (PRIME) designation by China, the U.S., and Europe for the treatment of TGCT that is not amenable to surgery. TGCT is a locally aggressive tumor. According to epidemiological data, its incidence rate rose from 28/million people in 1998 to 49/million people in 2012, and the number of new cases in China and the U.S. is about 60,000 and 14,000 people each year. Thus, many existing patients are in desperate need of drug treatment. TGCT mainly results in swelling, pain, stiffness, and decreased activity of the affected joints which seriously affect the patient's quality of life. There is currently no approved drug available in China, and only one drug has been approved in the U.S.. However, it is only available through the Risk Evaluation and Mitigation Strategy (REMS) Program due to potential liver injuries it may cause. There are unmet medical needs of TGCT patients in China, the U.S., and Europe.

A Phase Ia dose escalation study for pimicotinib has been completed in the U.S., followed by a Phase Ib multi-cohort expansion trial ongoing and a global Phase III MRCT trial initiated in China, the U.S. and Europe. In addition to TGCT, Abbisko Therapeutics is actively exploring the potential of pimicotinib in treating other indications including many types of solid tumors in clinic, and has obtained approval from NMPA to conduct a Phase II clinical study in chronic graft-versus-host disease and advanced pancreatic cancer, and also exploring its potential for treating Amyotrophic Lateral Sclerosis (“ALS”) and other CNS diseases. As of the date of this announcement, no highly selective CSF-1R inhibitor has been approved in China.

About TGCT

TGCT is a locally aggressive neoplasm which usually affects synovial joints, mucous sacs, and tendon membranes, resulting in swelling, pain, stiffness, and decreased activity of the affected joints which seriously affect the patient's quality of life¹. According to the 2013 World Health Organization classification, TGCTs were classified as localized TGCT and diffuse TGCT. Diffuse TGCT encompasses formerly known nodular tenosynovitis and pigmented villonodular synovitis (PVNS). Overexpression of CSF-1 occurs in most TGCTs. Surgical resection is the standard treatment for TGCT. However, not all patients are suitable for surgical treatment. It is difficult to remove tumors of diffuse TGCT patients by surgery, which may possibly lead to severe joint damage, total synovectomy, joint replacement, or even amputation, and the risk of surgical complications can be high. It has been reported that more than 50% of patients with diffuse TGCT will undergo recurrence after surgical resection². For TGCT patients not amenable to surgery, there is currently no approved drug available in China.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code on the Hong Kong Stock Exchange: 2256.HK), is an oncology-focused biopharmaceutical company founded in Shanghai, dedicated to discovering and developing innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of 15 innovative small molecule programs focused on precision oncology and immuno-oncology, including eight clinical stage assets.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

¹ Stacchiotti S, Dürr HR, Schaefer IM, et al. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts. *Cancer Treat Rev.* 2023;112:102491.

² Verspoor FG, van der Geest IC, Vegt E, Veth RP, van der Graaf WT, Schreuder HW. Pigmented villonodular synovitis: current concepts about diagnosis and management. *FutureOncol.* 2013;9(10):1515-1531.